Favorable Media Coverage Somewhat Unlikely to Impact Bioanalytical Systems (NASDAQ:BASI) Stock Price

News coverage about Bioanalytical Systems (NASDAQ:BASI) has been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.4430561576582 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Bioanalytical Systems (NASDAQ BASI) traded down $0.11 during mid-day trading on Friday, hitting $2.40. 18,730 shares of the stock were exchanged, compared to its average volume of 20,911. Bioanalytical Systems has a 1 year low of $0.69 and a 1 year high of $2.95. The company has a market cap of $20.57, a PE ratio of 24.00 and a beta of 0.98. The company has a current ratio of 0.69, a quick ratio of 0.57 and a debt-to-equity ratio of 0.57.

ILLEGAL ACTIVITY WARNING: “Favorable Media Coverage Somewhat Unlikely to Impact Bioanalytical Systems (NASDAQ:BASI) Stock Price” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2018/01/13/bioanalytical-systems-basi-receives-daily-media-sentiment-score-of-0-31.html.

Bioanalytical Systems Company Profile

Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply